Ternary Therapeutics

Ternary Therapeutics has secured £3.6 million in seed funding to accelerate the development of its artificial intelligence-driven platform for next-generation drugs.

Summary of transaction details:

• Value: £3.6 million
• Sector: Healthcare & Biotech
• Advisor: None
• Key Entities: Ternary Therapeutics, daphni
• Location: London, UK

Note: The investment reflects growing momentum across the biotechnology sector around targeted protein degradation, an approach that seeks to eliminate disease-causing proteins rather than simply blocking their activity.